PE20091964A1 - Encapsulacion de agentes biologicamente activos - Google Patents

Encapsulacion de agentes biologicamente activos

Info

Publication number
PE20091964A1
PE20091964A1 PE2009000608A PE2009000608A PE20091964A1 PE 20091964 A1 PE20091964 A1 PE 20091964A1 PE 2009000608 A PE2009000608 A PE 2009000608A PE 2009000608 A PE2009000608 A PE 2009000608A PE 20091964 A1 PE20091964 A1 PE 20091964A1
Authority
PE
Peru
Prior art keywords
encapsulation
biologically active
active agents
refers
hematoenephalic
Prior art date
Application number
PE2009000608A
Other languages
English (en)
Inventor
Andrew Robert Beaton
Ian Richard Catchople
Gerald Wayne Gough
Irene Papanicolaou
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40944671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091964(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20091964A1 publication Critical patent/PE20091964A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A NANOPARTICULAS, QUE COMPRENDEN: A) UNA SUSTANCIA FORMADORA DE PARTICULAS Y B) UNA PROTEINA TAL COMO UN ANTICUERPO DE DOMINIO QUE SE UNE A NOGO, ß-AMILOIDE O GLUCOPROTEINA ASOCIADA A MIELINA. TAMBIEN SE REFIERE A UN METODO PARA ENCAPSULAR DICHAS PROTEINAS Y COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENE PARA EL SUMINISTRO A TRAVES DE LA BARRERA HEMATOENCEFALICA, DICHAS NANOPARTICULAS SON UTILES EN EL TRATAMIENTO DE TRASTORNOS O ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL
PE2009000608A 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos PE20091964A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
PE20091964A1 true PE20091964A1 (es) 2010-01-09

Family

ID=40944671

Family Applications (4)

Application Number Title Priority Date Filing Date
PE2009000609A PE20091965A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000608A PE20091964A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000607A PE20091829A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000606A PE20091882A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2009000609A PE20091965A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2009000607A PE20091829A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000606A PE20091882A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos

Country Status (11)

Country Link
US (1) US20110064821A1 (es)
EP (2) EP2271323A2 (es)
JP (1) JP2011522792A (es)
KR (3) KR20110010760A (es)
AR (4) AR071634A1 (es)
CA (1) CA2721241A1 (es)
CL (4) CL2009001077A1 (es)
PE (4) PE20091965A1 (es)
TW (4) TW201006495A (es)
UY (4) UY31808A (es)
WO (1) WO2009135853A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201001568A1 (ru) * 2008-05-06 2011-10-31 Глаксо Груп Лимитед Инкапсуляция биологически активных агентов
US9504759B2 (en) 2011-08-11 2016-11-29 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
CA2946807A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
WO2015181344A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation of antigen-binding molecules
CA2951905A1 (en) * 2014-06-12 2015-12-17 Orbis Biosciences, Inc. Extended-release drug delivery compositions
AU2015280417B2 (en) 2014-06-24 2020-01-30 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
WO2020056323A1 (en) * 2018-09-13 2020-03-19 The Brigham And Women's Hospital, Inc. Nanoparticle formulations and methods of their use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833666A (en) 1986-12-24 1989-05-23 U.S. Philips Corporation Disc-record player suitable for scanning disc of different types
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
WO1994017789A1 (en) * 1993-02-15 1994-08-18 Shield Research Limited Polyalkylcyanoacrylate nanocapsules
AU7655194A (en) * 1993-09-09 1995-03-27 Schering Aktiengesellschaft Active principles and gas containing microparticles
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
DK1332209T3 (da) 2000-09-08 2010-03-29 Univ Zuerich Samlinger af repeatproteiner indeholdende repeatmoduler
WO2003005952A2 (en) * 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
WO2005003156A1 (en) 2003-07-04 2005-01-13 Affibody Ab Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
JP5006651B2 (ja) 2003-12-05 2012-08-22 ブリストル−マイヤーズ スクウィブ カンパニー ２型血管内皮増殖因子受容体の阻害剤
DK1796650T3 (da) 2004-09-14 2009-03-09 Nanodel Technologies Gmbh Transport- og afgivelsesvehikel indeholdende nanopartikler
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
CN101415729B (zh) 2006-03-30 2013-09-04 葛兰素集团有限公司 针对β-淀粉样蛋白肽的抗体
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
KR20100040840A (ko) 2007-06-06 2010-04-21 도만티스 리미티드 폴리펩티드，항체 가변 도메인 및 길항제

Also Published As

Publication number Publication date
JP2011522792A (ja) 2011-08-04
PE20091882A1 (es) 2009-12-24
WO2009135853A2 (en) 2009-11-12
CL2009001080A1 (es) 2010-09-24
US20110064821A1 (en) 2011-03-17
AR072668A1 (es) 2010-09-15
TW201006495A (en) 2010-02-16
CL2009001077A1 (es) 2010-09-24
EP2271323A2 (en) 2011-01-12
UY31808A (es) 2009-12-14
TW201012489A (en) 2010-04-01
EP2441447A1 (en) 2012-04-18
KR20110015604A (ko) 2011-02-16
PE20091965A1 (es) 2010-01-09
UY31810A (es) 2009-12-14
KR20110010758A (ko) 2011-02-07
UY31807A (es) 2009-12-14
KR20110010760A (ko) 2011-02-07
TW201012488A (en) 2010-04-01
CA2721241A1 (en) 2009-11-12
TW201012490A (en) 2010-04-01
AR072359A1 (es) 2010-08-25
CL2009001081A1 (es) 2010-09-24
UY31809A (es) 2009-12-14
CL2009001076A1 (es) 2010-09-24
PE20091829A1 (es) 2009-12-12
WO2009135853A3 (en) 2011-05-12
AR071633A1 (es) 2010-06-30
AR071634A1 (es) 2010-06-30

Similar Documents

Publication Publication Date Title
PE20091964A1 (es) Encapsulacion de agentes biologicamente activos
CY1125697T1 (el) Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
AR122746A2 (es) Una formulación farmacéutica líquida estable de anticuerpo
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
GT200700034A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
AR107014A1 (es) Formulación farmacéutica acuosa
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
CY1113934T1 (el) Σχηματισμος αποξηραμενου αναγεννημενου κυστιδιου για φαρμακευτικη εφαρμογη
CL2013000201A1 (es) Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular.
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
PE20190405A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4beta7
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
CL2012001966A1 (es) Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis.
CL2007003303A1 (es) Molecula de enlace para la proteina lingo-1; polinucleotido que la codifica; vector y celula que lo comprenden; composicion farmaceutica que comprende la molecula de enlace; y su uso para el tratamiento de lesiones del sistema nervioso central.
ES2542042R1 (es) Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
CL2012001349A1 (es) Uso de una composicion farmaceutica que comprende telmisartan para el tratamiento de hipertension sistemica en gatos ( div. sol. 2897-07).
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
ES2440393R1 (es) Un método para aumentar el efecto de una forma activada potenciada de un anticuerpo

Legal Events

Date Code Title Description
FD Application declared void or lapsed